Bivigam

PreclinicalBiologic

AADMA Biologics, Inc.

Bivigam is one of 8 biologic programs targeting Immunodeficiency Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Immunodeficiency DiseaseActive, not recruiting

Immunodeficiency DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Immunodeficiency Disease

#DrugCompanyPhaseTrials

Famvir

Novartis

Approved

—2

Epivir

GGlaxo Dba Glaxosmithkline

Approved

—3

Sustiva

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Retrovir

TAK-881

2 6

Ziagen

Other

1 8

Bivigam

AADMA Biologics, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Immunodeficiency Disease1 trial

A Study About Low Blood Pressure in Patients With Primary Immunodeficiency Disease Treated With Immune Globulin Products

Unknown status·AADMA Biologics, Inc.··NCT03037359·200 enrolled

Primary Immune Deficiency1 trial

Study to Evaluate Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Subjects Aged 2 to 16

Completed·AADMA Biologics, Inc.·Phase 4·NCT03164967·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Bivigam. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bivigam compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bivigam. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ADMA Biologics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: AADMA Biologics, Inc.

Bivigam

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Immunodeficiency Disease1 trial

Primary Immune Deficiency1 trial

References

Drug Info

Quick Facts

Related News